JGC
VRCA icon

J. Goldman & Co’s Verrica Pharmaceuticals VRCA Stock Holding History

J. Goldman & Co’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,700
Closed -$160K – 604
2024
Q1 		$160K Sell
2,700
-8,100
-75% -$447K 0.01% 373
2023
Q4 		$791K Buy
+10,800
New +$444K 0.03% 244

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

J. Goldman & Co's VRCA Position: Q2 2024 in Review

J. Goldman & Co sold out of Verrica Pharmaceuticals (VRCA) in Q2 2024, closing a stake of 2,700 shares — an estimated $160K sold.

J. Goldman & Co first reported a position in VRCA in Q4 2023 and held it in 2 quarters. The position peaked at $791K in Q4 2023. 74 funds tracked by Wall St. Rank hold VRCA as of Q2 2024.

  • J. Goldman & Co reported no remaining Verrica Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • J. Goldman & Co sold 2,700 Verrica Pharmaceuticals shares in Q2 2024, an estimated $160K.
  • J. Goldman & Co first reported a position in Verrica Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • J. Goldman & Co's Verrica Pharmaceuticals position peaked at $791K in Q4 2023.
  • 74 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2024.

Based on J. Goldman & Co's 13F filing for Q2 2024, filed 14 Aug 2024.